First Three Years’ Experience of Mucopolysaccharidosis Type-I Newborn Screening in California
Toki Fillman(California Department of Public Health), Stanley Sciortino(California Department of Public Health), Deepika Mathur(California Department of Public Health), Hao Tang(Stanford Health Care), Jamie Matteson(California Department of Public Health), Indranil Sen(College of Medicine & Sagore Dutta Hospital), Lisa Feuchtbaum(California Department of Public Health), Rana Zahedi(California Department of Public Health), Partha Neogi(California Department of Public Health), Richard S. Olney(University of Iowa), Tracey Bishop(California Department of Public Health)
Cited by 10
Related Papers
Guidelines for case classification for the national birth defects prevention study
|Birth Defects Research Part A Clinical and Molecular Teratology|2003|582
Sickle Hemoglobin (Hb S) Allele and Sickle Cell Disease: A HuGE Review
|American Journal of Epidemiology|2000|535
Use of Selective Serotonin-Reuptake Inhibitors in Pregnancy and the Risk of Birth Defects
|New England Journal of Medicine|2007|501
Vital Signs: Update on Zika Virus–Associated Birth Defects and Evaluation of All U.S. Infants with Congenital Zika Virus Exposure — U.S. Zika Pregnancy Registry, 2016
|MMWR Morbidity and Mortality Weekly Report|2017|299
Epidemiology of Biliary Atresia: A Population-based Study
|PEDIATRICS|1997|257